1. Pure red-cell aplasia and epoetin therapy
- Author
-
Benett, Charles L., McWilliams, Norene, Risch, Dennis W., Locatelli, Francesco, Luminari, Stefano, McKoy, June M., Evens, Andrew M., Rossert, Jerome, Nissenson, Allen R., Kim, Benjamin, Kuzel, Timothy M., Casadevall, Nicole, Tallman, Martin S., Lyons, Allison, Schumock, Glen T., Klinge, Stephen A., Trifilio, Steve M., and Belknap, Steven M.
- Subjects
United States. Food and Drug Administration -- Reports ,Eprex (Medication) -- Dosage and administration ,Epogen (Medication) -- Dosage and administration ,NeoRecormon (Medication) -- Dosage and administration ,Ectodermal dysplasia -- Causes of - Abstract
Reports of epoetin-associated pure red-cell aplasia from the Food and Drug Administration (FDA) and from the manufacturers of Eprex, Epogen and Neorecormon were obtained and analyzed. The results indicate a reduction of more than 80 percent in the incidence of pure red-cell aplasia due to Eprex.
- Published
- 2004